RU2006117298A - Визуализирующие агенты на основе ингибитора - Google Patents
Визуализирующие агенты на основе ингибитора Download PDFInfo
- Publication number
- RU2006117298A RU2006117298A RU2006117298/15A RU2006117298A RU2006117298A RU 2006117298 A RU2006117298 A RU 2006117298A RU 2006117298/15 A RU2006117298/15 A RU 2006117298/15A RU 2006117298 A RU2006117298 A RU 2006117298A RU 2006117298 A RU2006117298 A RU 2006117298A
- Authority
- RU
- Russia
- Prior art keywords
- imaging
- imaging agent
- radioactive
- alkyl
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 4
- 239000003795 chemical substances by application Substances 0.000 title claims 3
- 239000012216 imaging agent Substances 0.000 claims abstract 22
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims abstract 8
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims abstract 8
- 238000003384 imaging method Methods 0.000 claims abstract 7
- 238000002059 diagnostic imaging Methods 0.000 claims abstract 3
- 230000002285 radioactive effect Effects 0.000 claims 20
- 229910021645 metal ion Inorganic materials 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000003446 ligand Substances 0.000 claims 6
- 239000012217 radiopharmaceutical Substances 0.000 claims 6
- 229940121896 radiopharmaceutical Drugs 0.000 claims 6
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229910052755 nonmetal Inorganic materials 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- -1 halide ion Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 230000005298 paramagnetic effect Effects 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000004696 coordination complex Chemical class 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000007336 electrophilic substitution reaction Methods 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 238000012634 optical imaging Methods 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000011503 in vivo imaging Methods 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0326546.9A GB0326546D0 (en) | 2003-11-14 | 2003-11-14 | Inhibitor imaging agents |
| GB0326546.9 | 2003-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006117298A true RU2006117298A (ru) | 2007-12-20 |
Family
ID=29726529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006117298/15A RU2006117298A (ru) | 2003-11-14 | 2004-11-12 | Визуализирующие агенты на основе ингибитора |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070104644A1 (https=) |
| EP (1) | EP1682113B1 (https=) |
| JP (1) | JP5043438B2 (https=) |
| KR (1) | KR20060118479A (https=) |
| CN (1) | CN1901894A (https=) |
| AT (1) | ATE384519T1 (https=) |
| AU (1) | AU2004290950A1 (https=) |
| BR (1) | BRPI0416528A (https=) |
| CA (1) | CA2545267A1 (https=) |
| DE (1) | DE602004011553T2 (https=) |
| ES (1) | ES2299884T3 (https=) |
| GB (1) | GB0326546D0 (https=) |
| MX (1) | MXPA06005355A (https=) |
| NO (1) | NO20062118L (https=) |
| RU (1) | RU2006117298A (https=) |
| WO (1) | WO2005049005A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2007030012A2 (en) * | 2005-09-05 | 2007-03-15 | Stichting Voor De Technische Wetenscahappen | Extracellular matrix imaging |
| FR2891830B1 (fr) | 2005-10-07 | 2011-06-24 | Guerbet Sa | Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale |
| GB0520527D0 (en) * | 2005-10-10 | 2005-11-16 | Ge Healthcare Ltd | Automated method |
| EP1989179B1 (en) | 2006-02-15 | 2011-01-26 | Ge Healthcare As | Contrast agents |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| KR20080104347A (ko) * | 2006-03-29 | 2008-12-02 | 노파르티스 아게 | 선택적 히드록사메이트-기재 ｍｍｐ 억제제 |
| US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| GB0610395D0 (en) * | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| JP2010513476A (ja) * | 2006-12-20 | 2010-04-30 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 造影剤 |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| EP2119690A1 (en) * | 2008-05-14 | 2009-11-18 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Radiolabelled MMP selective compounds |
| JP5322527B2 (ja) * | 2008-07-17 | 2013-10-23 | 浜松ホトニクス株式会社 | アポトーシスの検出に適した化合物 |
| EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
| WO2010138720A2 (en) * | 2009-05-27 | 2010-12-02 | The Scripps Research Institute | Compounds and methods for chelating metals in aqueous solutions |
| US8962573B2 (en) | 2009-07-03 | 2015-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| US9023318B2 (en) * | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
| US8871189B2 (en) * | 2011-11-30 | 2014-10-28 | Mallinckrodt Llc | MMP-targeted therapeutic and/or diagnostic nanocarriers |
| CN103980277B (zh) * | 2014-05-27 | 2016-06-15 | 青岛大学 | 一种叶酸巯基化衍生物的制备方法 |
| GB202012671D0 (en) * | 2020-08-13 | 2020-09-30 | Nrf Ithemba Labs | Theranostic Compounds |
| TW202510874A (zh) | 2023-09-01 | 2025-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種大環化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714465A (en) * | 1989-05-19 | 1998-02-03 | Amgen Inc. | Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor |
| US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| ES2176913T3 (es) * | 1997-08-08 | 2002-12-01 | Pfizer Prod Inc | Derivados de acidos arilsulfonilaminohidroxamicos. |
| CA2299355C (en) * | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| IL127496A0 (en) * | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
| EP0952148B1 (en) * | 1998-04-10 | 2004-05-12 | Pfizer Products Inc. | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives |
| CA2378332A1 (en) * | 1999-08-18 | 2001-02-22 | Christopher Alan Conrad | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| IL138686A0 (en) * | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| WO2001092244A1 (en) * | 2000-05-30 | 2001-12-06 | Wayne State University | Inhibitors of matrix metalloproteinases |
| US8231858B2 (en) * | 2003-02-10 | 2012-07-31 | Ge Healthcare Limited | Diagnostic imaging agents with MMP inhibitory activity |
-
2003
- 2003-11-14 GB GBGB0326546.9A patent/GB0326546D0/en not_active Ceased
-
2004
- 2004-11-12 KR KR1020067009293A patent/KR20060118479A/ko not_active Withdrawn
- 2004-11-12 MX MXPA06005355A patent/MXPA06005355A/es unknown
- 2004-11-12 AT AT04798512T patent/ATE384519T1/de not_active IP Right Cessation
- 2004-11-12 EP EP04798512A patent/EP1682113B1/en not_active Expired - Lifetime
- 2004-11-12 AU AU2004290950A patent/AU2004290950A1/en not_active Abandoned
- 2004-11-12 US US10/560,371 patent/US20070104644A1/en not_active Abandoned
- 2004-11-12 CN CNA2004800403628A patent/CN1901894A/zh active Pending
- 2004-11-12 DE DE602004011553T patent/DE602004011553T2/de not_active Expired - Lifetime
- 2004-11-12 WO PCT/GB2004/004792 patent/WO2005049005A1/en not_active Ceased
- 2004-11-12 JP JP2006538954A patent/JP5043438B2/ja not_active Expired - Fee Related
- 2004-11-12 CA CA002545267A patent/CA2545267A1/en not_active Abandoned
- 2004-11-12 ES ES04798512T patent/ES2299884T3/es not_active Expired - Lifetime
- 2004-11-12 RU RU2006117298/15A patent/RU2006117298A/ru not_active Application Discontinuation
- 2004-11-12 BR BRPI0416528-4A patent/BRPI0416528A/pt not_active IP Right Cessation
-
2006
- 2006-05-11 NO NO20062118A patent/NO20062118L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004290950A1 (en) | 2005-06-02 |
| BRPI0416528A (pt) | 2007-01-09 |
| WO2005049005A1 (en) | 2005-06-02 |
| DE602004011553T2 (de) | 2009-03-26 |
| EP1682113B1 (en) | 2008-01-23 |
| DE602004011553D1 (de) | 2008-03-13 |
| JP5043438B2 (ja) | 2012-10-10 |
| EP1682113A1 (en) | 2006-07-26 |
| GB0326546D0 (en) | 2003-12-17 |
| US20070104644A1 (en) | 2007-05-10 |
| MXPA06005355A (es) | 2006-07-10 |
| NO20062118L (no) | 2006-05-11 |
| KR20060118479A (ko) | 2006-11-23 |
| ES2299884T3 (es) | 2008-06-01 |
| JP2007511494A (ja) | 2007-05-10 |
| ATE384519T1 (de) | 2008-02-15 |
| CA2545267A1 (en) | 2005-06-02 |
| CN1901894A (zh) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006117298A (ru) | Визуализирующие агенты на основе ингибитора | |
| CA1253799A (en) | Nmr contrast agents | |
| RU2006117819A (ru) | Новые агенты визуализации, содержащие ингибиторы каспазы-3 | |
| KR102843240B1 (ko) | 신규 psma-결합제 및 이의 용도 | |
| US10117954B2 (en) | Compositions and methods for in vivo imaging | |
| RU2011127467A (ru) | Са-ix специфические радиофармпрепараты для лечения и визуализации злокачественных опухолей | |
| CA3215134A1 (en) | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy | |
| IL125311A (en) | Metal complexes that contain perfluoroalkyl, a process for their production, a pharmaceutical composition containing the same and use thereof | |
| KR20180081558A (ko) | 장기간-지속되는 가돌리늄 기반 종양 표적화 이미징 및 치료 제제 | |
| JP7727384B2 (ja) | 分子イメージングのための二重標識プローブ及びその使用 | |
| JP2007511494A5 (https=) | ||
| RU2007110372A (ru) | Агенты визуализации, ингибирующие металлопротеиназу | |
| KR20250073273A (ko) | 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도 | |
| WO2019101729A1 (en) | A double-labeled probe for molecular imaging and use thereof | |
| JP2013514326A (ja) | 標識インテグリン結合剤 | |
| CA2077556A1 (en) | Lipophilic contrast agents for diagnostic image analysis | |
| JP7771080B2 (ja) | 医薬配合物 | |
| RU2005109272A (ru) | Улучшенные агенты визуализации, содержащие производные барбитуровой кислоты | |
| CA2265945A1 (en) | Labelled elastase inhibitors | |
| CA2615434A1 (en) | Perfluoroalkyl-containing complexes, process for their production as well as their use | |
| WO2017059060A1 (en) | Salicylic acid-based polymeric cest contrast agents targeting prostate-specific membrane antigen and uses thereof | |
| JP2009518373A (ja) | 線維症用の新規造影剤 | |
| JP2006505550A5 (https=) | ||
| RU2007118548A (ru) | Соединение для визуализации перфузии миокарда | |
| JP2011509294A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090415 |